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REAMBLE
edicine is experiencing an unprecedented focus on quanti-
ying and improving health care quality. The American Col-
ege of Cardiology (ACC) and the American Heart Associa-
ion (AHA) have developed a multifaceted strategy to facilitate
he process of improving clinical care. The initial phase of this
ffort was to create clinical practice guidelines that carefully
eview and synthesize available evidence to better guide patient
are. Such guidelines are written in a spirit of suggesting
iagnostic or therapeutic interventions for patients in most
ircumstances. Accordingly, significant judgment by clinicians
s required to adapt these guidelines to the care of individual
atients, and these guidelines can be generated with varying
egrees of confidence based upon available evidence. Occa-
ionally, the evidence supporting a particular structural aspect
r process of care is so strong that failure to perform such
ctions reduces the likelihood that optimal patient outcomes
ill occur. Creating a mechanism for quantifying these oppor-
unities to improve the outcomes of care is an important and
ressing challenge.
In the next phase of its quality improvement efforts, the
CC and the AHA created the ACC/AHA Task Force on
erformance Measures in February 2000 to spearhead the
evelopment of performance measures that allow the quality of
ardiovascular care to be assessed and improved. Three nom-
nees from each organization were charged with the task of
ssembling teams of clinical and methodological experts, both
rom within the sponsoring organizations and from other
rganizations dedicated to the care of patients covered by the
erformance measurement set. These writing committees were
iven careful guidance with respect to the necessary attributes
f good performance measures and the process of identifying,
onstructing, and refining these measures so that they can
ccurately achieve their desired goals (1).
The role of the performance measurement writing com-
ittee is not to perform primary evaluation of the medical
iterature. This is undertaken by ACC/AHA guidelines
ommittees. However, performance measurement writing
ommittees work collaboratively with guidelines committees
o that the guideline recommendations are written with a
egree of specificity that supports performance measure-
ent and so that new knowledge can be rapidly incorpo-
ated into performance measurement. Development of
CC/AHA guidelines includes a detailed review and rank-
ng of the evidence available for the diagnosis and treatment
f specific disease areas. Published guideline recommenda- Aions employ the ACC/AHA Classification of Recommen-
ations I, IIa, IIb, and III (Fig. 1).
So as not to duplicate performance measure development
fforts, writing committees are also instructed to evaluate
xisting nationally recognized performance measures using
he ACC/AHA “attributes of good performance measures.”
he measure specifications are adopted for those perfor-
ance measures that meet these criteria. Such measures
ave established validity, reliability, and feasibility and will
orm the foundation of the ACC/AHA measurement sets.
urthermore, writing committees are encouraged to identify
dditional performance measures that correspond to those
ey areas of quality proven to improve patient outcomes.
ACC/AHA Performance Measurement Sets are to be
pplied in either the inpatient and/or outpatient setting
epending on the topic. Inpatient measures are usually, but
ot always, captured by retrospective data collection; out-
atient reviews lend themselves to retrospective or prospec-
ive collection. The latter is itself a continuous quality
mprovement process. The performance measures quantify
xplicit actions performed in carefully specified patients for
hom adherence should be advocated in all but the most
nusual circumstances. In addition, the measures are con-
tructed with the intent to facilitate both retrospective and
rospective data collection using explicit administrative
nd/or easily documented clinical criteria, respectively. Fur-
hermore, the data elements required to construct the
erformance measures are identified and linked to existing
CC/AHA Clinical Data Standards to encourage the
tandardization of cardiovascular measurement.
While the focus of the performance measures writing
ommittee is to develop measures for internal quality
mprovement, it is appreciated that other organizations may
se these measures for external reporting of provider per-
ormance. Therefore, it is within the scope of the writing
ommittee’s task to comment on the strengths and limita-
ions of externally reporting potential performance mea-
ures. Specifically, this was done in the inpatient measure-
ent set, where a “Challenges to Implementation” section
as included subsequent to the specification, when appro-
riate (Appendix A).
All the measures contained in this set have limitations
nd challenges to implementation that might result in
nintended consequences when used for accountability pur-
oses. The implementation of these measures for purposes
ther than quality improvement (QI) require field testing to
ddress issues related to, but not limited to, sample size,
easonable frequency of use for an intervention, compara-
ility, and audit requirements. The way in which these
ssues are addressed will be highly dependent on the type of
ccountability system developed, including data collection
ethod, assignment of patients to physicians for measure-
ent purposes, baseline measure setting, incentive system,
nd public reporting method, among others. The ACC/
HA encourages those interested in working on implemen-
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ith the ACC/AHA to understand these complex issues in
ilot testing projects that can measure the impact of any
imitations and provide guidance on possible refinements of
he measures that would make them more suitable for
dditional purposes.
In the process of facilitating the measurement of cardio-
ascular health care quality, ACC/AHA Performance Mea-
urement Sets may serve as a vehicle for more rapidly
ranslating the strongest clinical evidence into practice.
hese documents are intended to provide practitioners with
tools” for measuring the quality of care and for identifying
pportunities to improve. Because the target audience and
nit of analysis for these measures is the practitioner, they
ere constructed from the provider’s perspective and were
ot intended to characterize “good” or “bad” practice, but to
e part of a system with which to assess and improve health
are quality. It is our hope that an application of these
erformance measures within a QI system will provide a
echanism through which the quality of medical care can
e measured and improved.
Robert O. Bonow, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Performance Measures
. INTRODUCTION
he ACC/AHA Heart Failure Performance Measures
riting Committee (hereafter, Writing Committee)
Figure 1. Applying classification ofas charged with the development of performance mea- bures concerning the diagnosis and treatment of heart
ailure (HF). These performance measures refer to both
ospitalized adult patients (age 18 years or older) with a
rincipal discharge diagnosis of HF and to adults with
F evaluated in the outpatient setting. The Writing
ommittee independently developed the inpatient
erformance measures for HF and collaborated with
he Physician Consortium for Performance Improve-
ent (Physician Consortium) to develop the outpa-
ient measures. In a concurrent process, the ACC/AHA
ask Force on Clinical Data Standards launched the
evelopment of the ACC/AHA Key Data Elements
nd Definitions for Measuring the Clinical Manage-
ent and Outcomes of Patients With Chronic Heart
ailure (2) intended to provide a standardized infor-
ational platform for clinical trials, clinical registries,
nd quality performance measurement for the condition
f HF.
. Scope of the Problem
eart failure is a major and growing public health problem in
he U.S. It affects 4.9 million people, and 550,000 new cases
re diagnosed each year (3). Heart failure is primarily a disease
f the elderly (4). Thus, the aging of the population and the
rolongation of the lives of cardiac patients by modern thera-
eutic innovations have led to an increasing incidence of HF.
he incidence of HF approaches 10 in 1,000 people over the
ge of 65, and hospital discharges for HF increased by 157%
mendations and level of evidence.etween 1979 and 2002 (3). In the U.S., the disorder is the
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illion hospital days each year (5).
Despite improvements in therapy, the mortality rate in
atients with HF has remained high, making implementa-
ion of therapies demonstrated to slow the progression of
F imperative. In 2001, 52,800 people died from HF as a
rimary cause (3). The variability in care documented in the
iterature demonstrates the opportunity for improvement,
hich makes performance measurement in cardiovascular
isease important.
The costs associated with HF are also large. Heart failure
s the most common Medicare diagnosis-related group
DRG), and more Medicare dollars are spent for diagnosis
nd treatment of HF than for any other diagnosis (6).
edicare reported paying $3.6 billion to beneficiaries for
are of HF in 1999, equating to $5,456 per discharge (3). It
as been estimated that in 2005, the total direct and indirect
ost of HF in the U.S. will be equal to $27.9 billion (3).
. Writing Committee Structure and Members
embers of the ACC/AHA Heart Failure Performance
easures Writing Committee included a senior clinician, a
ontent expert on HF performance measures, a statistician,
arious representatives from HF subspecialties, and repre-
entatives from the ACC/AHA Heart Failure Guideline
pdate Writing Committee and ACC/AHA Heart Failure
linical Data Standards Writing Committee to ensure
onsistency across the documents. The Writing Committee
lso included members of the Heart Failure Society of
merica (HFSA), the American Academy of Family Prac-
itioners (AAFP), the American College of Physicians
ACP), and a nurse scientist from the Nursing Council of
he American Heart Association.
. Relationships With Industry
he work of the Writing Committee was supported exclu-
ively by the ACC and the AHA. Writing Committee
embers volunteered their time, and there was no commer-
ial support. Meetings of the Writing Committee were
onfidential and attended only by committee members and
taff. All Writing Committee members with relationships
ith industry relevant to this topic declared these in writing
ccording to standard ACC and AHA reporting require-
ents; additionally, members verbally acknowledged these
elationships to the Writing Committee. Please see Appen-
ix D for relevant Writing Committee relationships with
ndustry. The collaboration with the Physician Consortium
o develop the outpatient measures received additional
olunteer support from Physician Consortium members and
taff support from the American Medical Association.
lease see Appendix E for ACC/AHA/Physician Consor-
ium Writing Group relevant relationships with industry. In
ddition, Appendix F includes relevant relationships with
ndustry information for all peer reviewers of this document. o. Review and Endorsement
he previously published outpatient ACC/AHA/Physician
onsortium Heart Failure Clinical Performance Measures
7) underwent a period of public comment from January 22,
003 through February 12, 2003, peer review and approval
rom the respective boards of the ACC and the AHA, and
pproval by the Physician Consortium. These outpatient
easures are being validated through pilot testing as part of
he Doctors’ Office Quality (DOQ)–Information Technol-
gy Project of the Centers for Medicare and Medicaid
ervices (CMS). Some clarifications, modifications, and
dditions to the published ACC/AHA/Physician Consor-
ium HF outpatient measures have been made in this
ocument and have been incorporated in their updated
CC/AHA/Physician Consortium Heart Failure Clinical
hysician Performance Measurement Set.
During the period February 3, 2005 to March 4, 2005,
he complete ACC/AHA HF measurement set, incorpo-
ating both inpatient and outpatient measures, underwent a
0-day public comment period during which time ACC and
HA members, as well as other health professionals, had an
pportunity to review and comment on the document in
dvance of its final approval and publication. Over 30
esponses were received. The official peer and content
eview of the document was conducted simultaneously with
he 30-day public comment period, with three peer review-
rs nominated by the ACC and three reviewers nominated
y the AHA. Additional comments were sought from
linical content experts and performance measurement ex-
erts.
The ACC/AHA Clinical Performance Measures for the
are of Adults with Chronic Heart Failure was adopted by
he respective boards of the ACC and AHA in August
005. These measures will be reviewed for currency once a
ear and will be updated as needed. They will be considered
alid until they are updated or rescinded by the ACC/AHA
ask Force on Performance Measures.
I. METHODOLOGY
he development of performance measures involves identi-
cation of a set of measures targeted toward a particular
atient population, observed over a particular care period.
o achieve this goal, the ACC/AHA Task Force on
erformance Measures has outlined and published a meth-
dology of sequential tasks that performance measures
riting committees are required to complete (1). The
ollowing sections delineate how the Writing Committee
pplied this methodology to the topic of HF.
. Definition of HF
he ACC/AHA 2005 Guideline Update for the Diag-
osis and Management of Chronic Heart Failure in the
dult (ACC/AHA 2005 HF Guideline Update) (8)
lassified HF into four stages (Table 1). For the purpose
f this document, only the latter two stages, which qualify
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ere considered for inclusion in the measure population.
hus, the inpatient and outpatient performance measure-
ent sets do not apply to patients for whom established
isk factors and structural disorders occur without left
entricular systolic dysfunction or symptoms associated
ith HF (Stages A and B). In addition, specific diagnosis
odes, based on ICD-9-CM (Table 2) should be used to
creen and select the inpatient target patient population.
hese codes correspond to the Joint Commission on
ccreditation of Healthcare Organizations (JCAHO)
nd Centers for Medicare and Medicaid Services (CMS)
able 1. Stages of HF
tage
A Patients at high risk for HF but without structural hea
disease, diabetes, obesity, and metabolic syndrome or p
patients have no identified structural or functional abn
shown signs or symptoms of HF.
B Patients who have developed stuctural heart disease th
infarction, LV remodeling including LVH and low EF
C Patients with stuctural disease who have current or pri
breath and fatigue, reduced exercise tolerance).
D Patients with refractory HF requiring specialized interv
therapy—those who are recurrently hospitalized or can
able 2. ACC/AHA Heart Failure Performance Measures
CD-9-CM Diagnosis Codes
ICD-9-CM
Code Description
402.01 Malignant, hypertensive heart disease with heart failure
402.11 Benign, hypertensive heart disease with heart failure
402.91 Unspecified, hypertensive heart disease with heart failure
404.01 Malignant, hypertensive heart and renal disease with
heart failure
404.03 Malignant, hypertensive heart and renal disease with
heart failure and renal failure
404.11 Benign, hypertensive heart and renal disease with heart
failure
404.13 Benign, hypertensive heart and renal disease with heart
failure and renal failure
404.91 Unspecified, hypertensive heart and renal disease with
heart failure
404.93 Unspecified, hypertensive heart and renal disease with
heart failure and renal failure
428.00 Unspecified, congestive heart failure
428.01 Left heart failure
428.09 Unspecified, heart failure
428.20 Unspecified, systolic heart failure
428.21 Acute systolic heart failure
428.22 Chronic systolic heart failure
428.23 Acute or chronic systolic heart failure
428.30 Unspecified, diastolic heart failure
428.31 Acute diastolic heart failure
428.32 Chronic diastolic heart failure
428.33 Acute or chronic diastolic heart failure
428.40 Unspecified, combined systolic and diastolic heart failure
428.41 Acute combined systolic and diastolic heart failure
428.42 Chronic combined systolic and diastolic heart failure
428.43 Acute or chronic combined systolic and diastolic heartfailureF cohort selection codes (i.e., the ICD-9-CM codes
reviously defined by JCAHO and CMS to screen and
elect cohorts for HF performance measures).
. Dimensions of Care
iven the multiple domains of providing treatment that can
e measured, the Writing Committee identified and explic-
tly articulated the relevant dimensions of care that should
e evaluated. As part of the methodology, each potential
erformance measure was categorized into its relevant
imension of care. Classification into dimensions of care
acilitated identification of areas where evidence was lack-
ng, as well as prevented duplication of measures within the
et. Diagnostics, Patient Education (including prognosis
nd etiology), Treatment, and Self-Management were se-
ected as the relevant dimensions of care for HF perfor-
ance measures in both the inpatient and outpatient
ettings. A fifth dimension, Monitoring of Disease Status,
as been addressed for the outpatient setting but will be
valuated in the future for the inpatient setting and might
nclude items such as documentation of follow-up appoint-
ents. The Writing Committee exclusively focused on
rocesses and did not consider outcomes since the purpose
f the measures is to assist physicians in improving specific
linical care.
. Literature Review
he Writing Committee reviewed the ACC/AHA 2005
F Guideline Update (8) as the primary source for deriving
he measures. In addition, the Writing Committee reviewed
urrent national performance measures and other relevant
iterature from organizations developing clinical guidelines
nd quality standards, including:
JCAHO/CMS Heart Failure Performance Measures (9);
Final Report of the Study of Clinically Relevant Indica-
tors for Pharmacologic Therapy (SCRIPT) Project:
Congestive Heart Failure (10);
AHA/ACC Conference Proceedings: Evaluating Qual-
ity of Care for Patients With Heart Failure (11);
Team Management of Patients With Heart Failure: A
Description
ease or symptoms of HF (e.g., patients with hypertension, atheroclerotic
ts using cardiotoxins or with a family history of cardiomyopathy). Such
ities of the pericardium, myocardium, or cardiac valves and have never
tongly associated with the development of HF (e.g., previous myocardial
symptomatic valvular disease) but without signs or symptoms of HF.
ptoms of HF (e.g., known structural heart disease and shortness of
ns (e.g., marked symptoms of HF at rest despite maximal medical
e safely discharged from the hospital without specialized interventions).rt dis
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Association (12);
Heart Failure Society of America (HFSA) Guidelines for
Management of Patients With Heart Failure Caused by
Left Ventricular Systolic Dysfunction—Pharmacological
Approaches (13); and
RAND Health: Quality of Care for Cardiopulmonary
Conditions: A Review of the Literature and Quality
Indicators: Chapter 9, Heart Failure (14).
. Definition and Selection of Measures
xplicit criteria exist for the development of performance
easures so that they accurately reflect the quality of care,
ncluding quantification of the numerators and denomina-
ors and clearly evaluating the interpretability, applicability,
nd feasibility of the proposed measures. To determine
hich measures will be selected for inclusion in the perfor-
ance measurement set, the committee identified the Class
and Class III recommendations from the ACC/AHA
005 HF Guideline Update (8) and specific relevant state-
ents from the Team Management of Patients With Heart
ailure: A Statement for Healthcare Professionals From the
ardiovascular Nursing Council of the American Heart
ssociation (12).
Once these recommendations were identified, the Writing
ommittee rated their potential for use as performance mea-
ures utilizing the Rating Form and Guide (Appendix C).
riting Committee members rated 27 potential measures on
3 dimensions using 5-point Likert scales (1  lowest rating;
 highest rating) against the ACC/AHA attributes for
atisfactory performance measures (Table 3) (15).
The rating results of the final question on the rating form,
Overall Assessment,” were used to make the final determi-
ation for inclusion of a potential measure in the HF
easurement set. Any measure that received a full commit-
able 3. ACC/AHA Attributes for Satisfactory Performance
easures
ACC/AHA Attributes for Satisfactory Performance Measures
Useful in improving patient outcomes
1. Evidence-based
2. Interpretable
3. Actionable
Measure design
1. Denominator precisely defined
2. Numerator precisely defined
3. Validity
a. Face validity
b. Content validity
c. Construct validity
4. Reliability
Measure implementation
1. Feasibility
a. Reasonable effort
b. Reasonable cost
c. Reasonable time period for collection
Overall assessmentee consensus rating of 3 or above in this area (“Overall tssessment”) was advanced to the final measure set. Based
n the results, 7 inpatient measures and 12 outpatient
easures were advanced. These measure sets were then
valuated in light of the ACC/AHA 2005 HF Guideline
pdate (8) to determine where measures should be revised
nd clarified. The Discussion section and measurement set
pecifications (Appendix A and B) detail the rationale for
odifications based on the ACC/AHA 2005 HF Guideline
pdate (8).
II. INPATIENT HF MEASURES
. Inpatient Population and Care Period
he inpatient target population consists of patients age 18
ears or older with a principal discharge diagnosis of HF
ased on ICD-9-CM (see Table 2). A set of exclusion
riteria specific to each inpatient measure was developed.
or all the inpatient measures, patients who were under 18
ears of age, were transferred to another acute care facility,
ho left against medical advice, who were discharged to
ospice, or who died during the index admission are
xcluded.
The general period of assessment is the related inpatient
ospitalization. The specific time period of interest for each
easure is further defined in Appendix A and ranges from
ithin 30 minutes of the index admission to the hospital
ischarge.
. Brief Summary of the Inpatient Measures
able 4 lists the ACC/AHA Heart Failure Performance
easures Inpatient Measurement Set. The inpatient mea-
urement set includes the dimensions of care referenced in
he ACC/AHA Methodology for the Selection and Cre-
tion of Performance Measures article (1), with the excep-
ion of Monitoring of Disease Status (Table 5). Although
o current measure exists for this dimension for the inpa-
ient setting, future measure development efforts will exam-
ne how to address this gap in the measurement set.
Appendix A provides detailed specifications for each
npatient performance measure including numerator, de-
ominator, period of assessment, method of reporting,
ources of data, rationale, clinical recommendations, and
hallenges to implementation.
. Inpatient Data Collection Instruments
o aid in data compilation, a data collection instrument is
ecommended. A sample instrument is provided in Table 6.
his instrument was created to accompany the associated
easures; however, individual institutions may need to
odify this instrument or develop a different one based on
heir local practice patterns and standards. The flowsheet is
ntended for prospective data collection only. It is not
esigned to meet the reporting requirements of organiza-
ions, such as JCAHO or CMS.
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. Outpatient Population and Care Period
he target population consists of patients age 18 years or
lder with at least one primary outpatient visit for HF,
ocumentation of HF in the medical records as the primary
eason for their visit, or with a principal diagnosis of HF. In
ddition, patients with documentation of symptoms consis-
ent with Stage C or Stage D HF (Table 1) should be
ncluded. A set of exclusion criteria specific to each outpa-
ient measure was developed to further specify the target
opulation (Appendix B).
For the purpose of this document, the outpatient care
eriod is defined as the care provided in an outpatient
etting within the time period under evaluation (reporting
ear).
. Brief Summary of the Outpatient Measures
he outpatient performance measurement set for HF (Ta-
le 7) was developed, revised, and approved through collab-
rative efforts among the ACC, AHA, and the Physician
onsortium. The ACC/AHA Heart Failure Performance
easures Writing Committee drafted the candidate outpa-
ient measures that were published by the Physician Con-
ortium in 2003 (7) and were reviewed for update in 2005.
lthough these outpatient measures, have been previously
able 4. ACC/AHA Heart Failure Performance Measures: Inpat
Performance Measure Name
. Evaluation of left ventricular
systolic (LVS) function
Heart failure patients wi
before arrival, during hos
. ACE inhibitor (ACEI), or
angiotensin receptor blocker
(ARB) for LVSD
Heart failure patients wi
prescribed an ACEI or A
. Anticoagulant at discharge
for HF patients with atrial
fibrillation (AF)
Heart failure patients wi
prescribed warfarin at dis
. Discharge instructions Heart failure patients dis
patient or caregiver at di
level, diet, discharge med
symptoms worsen.
. Adult smoking cessation
advice/counseling
Heart failure patients wi
counseling during hospit
able 5. ACC/AHA Heart Failure Performance Measurement S
Performance Measure Diagnostics E
. Evaluation of left ventricular systolic
function (LVS) function
✓
. ACE inhibitor (ACEI) or angiotensin
receptor blocker (ARB) for LVSD
. Anticoagulant at discharge for HF
patients with atrial fibrillation (AF)
. Discharge instructions
. Adult smoking cessation
advice/counsellingAlthough no current measure exists for this dimension for the inpatient setting, future measurublished (7), the outpatient measurement set included in
his document reflects some changes to the outpatient
easures based on the evidence review from the 2005
CC/AHA HF Guideline Update (8).
As shown in Table 8, the outpatient measurement set
ncludes measures for each of the dimensions of care
eferenced in the ACC/AHA Methodology for the Selec-
ion and Creation of Performance Measures article (1).
Appendix B provides detailed specification for each
utpatient performance measure including numerator,
enominator, period of assessment, method of reporting,
ources of data, rationale, clinical recommendations, and
hallenges to implementation. Through ongoing efforts,
any of the outpatient measures are under consideration
or widespread implementation/endorsement by national
ealthcare organizations (e.g., National Quality Forum
NQF] and the Ambulatory Care Quality Alliance
AQA]).
. Outpatient Data Collection Instruments
he outpatient HF performance measures are intended to
e used prospectively to enhance the QI process. To aid in
ata compilation, a data collection instrument is recom-
ended. A sample instrument is provided in Figure 2,
hich was developed by the Physician Consortium and
dapted to correspond to the outpatient measures included
Measure Descriptions
Measure Description
umentation in the hospital record that LVS function was assessed
zation, or is planned after discharge.
SD and without both ACEI and ARB contraindications who are
t hospital discharge.
onic/recurrent AF and without warfarin contraindications who are
e.
ed home with written instructions or educational material given to
e or during the hospital stay addressing all of the following: activity
ns, follow-up appointment, weight monitoring, and what to do if
istory of smoking cigarettes, who are given smoking cessation advice or
.
imensions of Care Inpatient Measures Matrix
nt
ion Treatment
Self-
Management
Monitoring of
Disease Status*
✓
✓
✓ient
th doc
pitali
th LV
RB a
th chr
charg
charg
scharg
icatio
th a het: D
Patie
ducat
✓
✓e development efforts will examine how to address this gap in the measurement set.
T1
L
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A
A
A
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A
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ACC/AHA Heart Failure Performance Measures Inpatient Data Collection Flowsheet
. Left ventricular systolic (LVS) function assessment YES NO
V1. Was an assessment of left ventricular systolic (LVS) function made in diagnosed HF
patients, LVS documented as assessed before arrival, during hospitalization, or planned
for after discharge?...................................................................................................................
Œ
(go to LV2)
Œ
(go to 4)
V2.  Quantitative EF:______%: ______
Qualitatively assessed as (circle one):
Normal Mildly Depressed Moderately Depressed Severely Depressed
. ACE inhibitor or ARB therapy for left ventricular systolic dysfunction (“ACE/ARB”) at discharge YES NO
CE/ARB1. Was ejection fraction 40% or with moderately or severely depressed left ventricular
systolic function? ......................................................................................................................
Œ Œ
(go to 3)
CE/ARB2. Was ACE inhibitor prescribed upon discharge?..................................................................... Œ
(go to 3)
Œ
(go to ACE/ARB3)
CE/ARB3. Was ARB prescribed upon discharge? .................................................................................... Œ
(go to 3)
Œ
(go to ACE/ARB4)
CE/ARB4. Reasons documented by physician, nurse practitioner, or physician assistant for not
prescribing ACE inhibitor and ARB?.....................................................................................
Œ Œ
. Anticoagulant use for heart failure and atrial fibrillation (“ACU”) YES NO
CU1. Chronic or recurrent atrial fibrillation documented?............................................................... Œ
(go to ACU2)
Œ
(go to 4)
CU2. If yes, was warfarin prescribed? ............................................................................................... Œ
(go to 4)
Œ
(go to ACU3)
CU3. Reasons documented by physician, nurse practitioner, or physician assistant for not
prescribing warfarin? ................................................................................................................
Œ Œ
(go to 4)
. Discharge instructions (“PE”) YES NO
E1. Patient discharged with complete written discharge instructions, as documented in the medical
record? ......................................................................................................................................
Œ Œ
(go to 5)
. Adult smoking cessation advice/counseling (“SC”) YES NO
C1. Adult patient who smokes cigarettes given smoking cessation counseling/advice? ................ Œ Œhis flowsheet is intended for prospective data collection only. It is not designed to meet the reporting requirements of organizations, such as the Joint Commission on
ccreditation of Healthcare Organizations (JCAHO) or the Centers for Medicare and Medicaid Services (CMS).
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odify the instrument or develop a different tool, based on
heir local practice patterns and standards.
. DISCUSSION
he ACC/AHA Clinical Performance Measures for Adults
ith Chronic Heart Failure address many of the same
rocesses of care as earlier measurement sets published by
ther organizations. The Writing Committee has been
ognizant of the previous efforts of other groups and sought
o enhance and clarify measures in ways that reflect the
able 7. ACC/AHA/Physician Consortium for Performance Imp
utpatient Measure Descriptions
Performance Measure Name
1. Initial laboratory tests Initial labora
2. Left ventricular systolic (LVS) function
assessment
Heart failure
3. Weight measurement Measuremen
4. Blood pressure measurement Measuremen
5. Assessment of clinical symptoms of
volume overload (excess)
Assessment o
6. Assessment of clinical signs of volume
overload (excess)
Completion
diagnosed wi
7. Assessment of activity level Evaluation o
8. Patient education Percentage o
and health b
9. Beta-blocker therapy Prescription
(LVSD).
0. ACE inhibitor or angiotensin receptor
blocker (ARB) therapy for patients with
heart failure who have left ventricular
systolic dysfunction (LVSD)
Prescription
LVSD.
1. Warfarin therapy for patients with atrial
fibrillation (AF)
Use of warfa
able 8. ACC/AHA/Physician Consortium for Performance Imp
imensions of Care Outpatient Measures Matrix
Performance Measure Name Diagnostics
1. Initial laboratory tests ✓
2. Left ventricular systolic function (LVSF)
assessment
✓
3. Weight measurement ✓
4. Blood pressure measurement ✓
5. Assessment of clinical sysmptoms of volume
overload (excess)
6. Assessment of clinical signs of volume
overload (excess)
✓
7. Assessment of activity level
8. Patient education
9. Beta-blocker therapy
0. ACE inhibitor, or angiotensin receptor
blocker (ARB) therapy for patients with HF
who have left ventricular systolic dysfunction
(LVSD)
1. Warfarin therapy for patients with atrial
fibrillation (AF)dvancement of the underlying science, the complexity of
are, and the challenges of accurate and complete data
ollection. In particular, the current document incorpo-
ates the performance measures developed jointly by
MS and JCAHO for management of patients with
F (9).
The Writing Committee recognizes that not all Class I
uideline recommendations lend themselves to becoming
xcellent performance measures, as many do not easily fit
he attributes of performance measures in terms of useful-
ess, accuracy, feasibility, and measurability. Thus, the
ment Heart Failure Performance Measurement Set:
Measure Description
veluation of patients with newly diagnosed HF.
nts with documentation that LVS has been assessed.
atient’s weight at each outpatient visit to assess change in volume status.
atient’s blood pressure at each outpatient visit.
ical symptoms of volume overload at each outpatient visit.
hysical examination pertaining to volume status assessment in patients
at each outpatient visit.
impact of HF on activity level at each outpatient visit.
nts who were provided with patient education on disease management
r changes during one or more visits within the period of assessment.
a-blockers in patients with HF and left ventricular systolic dysfunction
E inhibitor or ARB for management of outpatient HF patients with
patients with both HF and AF.
ment Heart Failure Performance Measurement Set:
Patient
ducation Treatment
Self-
Management
Monitoring of
Disease Status
✓
✓
✓ ✓
✓
✓
✓rove
tory e
patie
t of p
t of p
f clin
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September 20, 2005:1144–78 Chronic Heart Failure in the Adult: ACC/AHA Performance MeasuresFigure 2. ACC/AHA and Physician Consortium data collection flowsheet. Continued on next page.
Located in flowsheet only for quality improvement. aStandardized scale or assessment tools may include the New York Heart Association functional
lassification of congestive heart failure questionnaire (Guyatt). bPatient education should include one or more of the following: weight monitoring; diet
sodium restriction); symptom management; physical activity; smoking cessation; medication instruction; minimizing or avoiding use of NSAIDs; follow-up
lans (e.g., next appointment, visiting nurse); referral for specific educational or management programs; or prognosis/end-of-life issues.
This flowsheet is intended for prospective data collection only. It is not designed to meet the reporting requirements of organizations, such as the Joint
ommission on Accreditation of Healthcare Organization (JCAHO) or the Centers for Medicare and Medicaid Services (CMS). ©2003 American Medical
ssociation (modified by the ACC/AHA HF Performance Measures Writing Committee with permission from the Physician Consortium).
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ations that were considered to perform well as performance
easures in the inpatient or outpatient setting. However, in
he case of angiotensin-converting enzyme (ACE) inhibi-
or/angiotensin receptor blocker (ARB) measures, a Class
Ia recommendation was considered and used as the basis
or clarifying the measure constructed by the committee.
lthough Class IIa recommendations are not considered for
tand-alone measures, in some cases, such as this one, they
rovide additional information about valid alternative ther-
pies that are considered by the committee for inclusion in
measure set. This change is made with recognition that
lthough ACE inhibitors are preferred as the first option in
F patients who have left ventricular systolic dysfunction
LVSD), physicians should be given credit for prescribing or
ontinuing ARB therapy.
The support for use of ARBs in patients with HF and
educed left ventricular ejection fraction has evolved signif-
cantly in response to published clinical trials that showed
RBs as an effective alternative therapy (16) and is recom-
ended in the ACC/AHA 2005 HF Guideline Update (8)
s a reasonable alternative therapy. Thus, the Writing
ommittee decided to revise both the inpatient and outpa-
ient ACE inhibitor measures to include ARB therapy.
The inpatient and outpatient measures are designed to be
mplemented in either a retrospective chart abstraction
rocess or used as part of a prospective quality improvement
rocess. The data collection tool suggested for use with the
npatient measures (Table 6) permits prospective data cap-
ure, as well, and promotes the prospective identification of
F patients. For example, documentation of patient edu-
ation is often difficult to obtain in a retrospective chart
eview, but can be easily implemented using a prospective
atient management tool. These inpatient and outpatient
easures will require testing in practice to determine their
alidity and may require modification in the future.
The Writing Committee also felt it was important to add
xclusion criteria to the measures to recognize that there are
ustifiable medical and patient reasons for not meeting the
erformance measures. In the inpatient set, these reasons
hould be included in the “reasons documented by physi-
ian, nurse practitioner, or other healthcare provider for
ot. . . .” In the outpatient set, medical and patient reasons
or not meeting the measure are listed separately. Docu-
entation of such factors should be encouraged and will
rovide valuable data for future research and conducting
n-depth quality improvement for situations where there
eem to be outliers with respect to the number of patients
ith medical or patient-centered exclusions for the perfor-
ance measures.
Challenges to implementation of measures are discussed,
here applicable. In general, inadequate documentation is
he initial challenge of any measurement effort. The fact
hat these challenges are discussed is not intended as an
rgument against measurement. Rather, they should be
onsidered as cautionary notes that draw attention to areas ahere additional focus on research and improvement of the
easures should be considered.
. ICD Potential Measure
lthough the committee considered a number of additional
otential measures that focus on equally important aspects of
are, either the evidence base or more significant challenges to
easurement of these components of care across all patients
ndermined the benefits that might be gained. Such is the case
or measurement of implantable cardioverter-defibrillator
ICD) implantation for the reduction of sudden death in
atients with severe LVSD and biventricular pacing in appro-
riate candidates. Currently, there is not a sufficient number of
ualified cardiac electrophysiologists in every community to
mplant ICDs and monitor follow-up in these HF patients as
ell as to ensure that complications are addressed as these
atients progress from HF Class III to Class IV.
. Inpatient Beta-Blocker Potential Measure
he Writing Committee also considered including an
npatient beta-blocker therapy measure. There is no specific
uideline recommendation for implementation of beta-
lockers in the inpatient setting, although it is recom-
ended that such medications be started when patients are
linically stable. The complexities of establishing the right
onditions under which stable HF patients would be in-
luded in the measure minus the exclusions would result in
o small a denominator that the measure would not be
eaningful at this time. The omission of an inpatient
eta-blocker measure does not recommend against its ini-
iation in hospitals for appropriate patients.
. Measures Removed From the Measurement Set
hree measures were removed from the measurement sets
inpatient and outpatient) post-peer review/public com-
ent, i.e., the “Volume Status and Clinical Assessment on
dmission” and “Initial Evaluation of Left Ventricular
ystolic Function for Newly Diagnosed HF Patients” mea-
ures from the inpatient set, and the “Examination of the
eart” measure from the outpatient set. These measures,
lthough potentially of value for improving patterns of care,
ere not believed to have been tested in clinical situations to
ssure their reliability and validity.
To be successful as quality improvement tools, these
easures need to be adopted, implemented, and integrated
nto the patient care. These measurement sets should
ontribute to the evolution of reporting systems that allow
hysicians and other health care providers to improve
reatment for a critical patient population. Quality improve-
ent is a continuous process, and this document reflects the
essons the practicing community has learned to date in
sing existing measures and knowledge gained about how
hey might be improved. The clinical care team should
ollect data and review adherence to these measures on a
outine basis, look for changes, and adjust practice patterns
s necessary to improve performance.
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1. Evaluation of Left Ventricular Systolic (LVS) Function
Heart failure patients with documentation in the hospital record that LVS function was assessed before arrival,
during hospitalization, or is planned for after discharge
umerator Heart failure patients with documentation in the hospital record that LVS function was assessed before arrival, during
hospitalization, or is planned for after discharge. Description of left ventricular systolic function may be quantitative
(ejection fraction) or qualitative (for example, “moderately depressed” or visually estimated ejection fraction).
enominator Heart failure patients.
Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for heart failure as defined in Table 3.
Excluded populations:
● Patients less than 18 years of age;
● Patients transferred to another acute care hospital or federal hospital;
● Patients who expired;
● Patients who left against medical advice;
● Patients discharged to hospice;
● Patients with reason(s) documented by a physician, nurse practitioner, or physician assistant for no LVS
function assessment.
eriod of assessment Inpatient admission.
ources of data Administrative data and medical records.
Rationale
valuation of patients with heart failure should include a measurement of left ventricular systolic function. Patients with LVEF less than 40% or with
oderately or severely depressed left ventricular systolic function are generally considered to warrant consideration of specific therapy. LVS function assessed
t the time of heart failure diagnosis can be considered valid unless the patient has had a change in clinical status, experienced or recovered from a clinical
vent, or received treatment that might have a significant effect on cardiac function.
he single most useful diagnostic test in the evaluation of patients with HF is the comprehensive two-dimensional echocardiogram coupled with Doppler flow
tudies to determine whether the primary abnormality is pericardial, myocardial, or valvular. A comprehensive echocardiographinc evaluation is important, since
t is common for patient to have more than on cardiac abnormality that contributes to the development of HF. Furthermore, the study serves as a baseline for
omparison to assess long-term effects of therapeutic interventions or changes associated with significant clinical events.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
wo-dimensional echocardiography with Doppler should be performed during initial evaluation of patients presenting with HF to assess LVEF, LV size,
all thickness, and valve function. Radionuclide ventriculography can be performed to assess LVEF and volumes (Level of Evidence: C).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
Challenges to Implementation
onfirming results of LVS function assessment if conducted before arrival or planned after discharge.
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Systolic Dysfunction (LVSD)
Heart failure patients with LVSD and without both ACEI and ARB contraindications who are prescribed
an ACEI or ARB at hospital discharge
[For purposes of this measure, LVSD is defined as chart documentation of LVEF less than 40% or a narrative description
of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.]
umerator Heart failure patients who are prescribed an ACEI or ARB at hospital discharge.
enominator Heart failure patients with LVSD and without both ACEI and ARB contraindications
Included populations:
● Discharges with an ICD-9-CM Principal Diagnosis Code for heart failure as defined in Table 3, AND
● Chart documentation of a LVEF less than 40% or a narrative description of LVS function consistent with moderate or
severe systolic dysfunction.
Excluded populations:
● Patients less than 18 years of age;
● Patients transferred to another acute care hospital or federal hospital;
● Patients who expired;
● Patients who left against medical advice;
● Patients discharged to hospice;
● Patients with BOTH a potential contraindication/reason for not prescribing an ACEI at discharge AND a potential
contraindication/reason for not prescribing an ARB at discharge, as evidenced by one or more of the following:
– ACEI allergy AND ARB allergy,
– Moderate or severe aortic stenosis,
– Physician, nurse practitioner, or physician assistant documentation of BOTH a reason for not prescribing an ACEI at
discharge AND a reason for not prescribing an ARB at discharge,
– Reason documented by physician, nurse, or other healthcare provider for not prescribing an ARB at discharge AND an
ACEI allergy,
– Reason documented by physician, nurse practitioner, or physician assistant for not prescribing an ACEI at discharge
AND an ARB allergy.
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
CE inhibitors have been shown to decrease morbidity, mortality, and hospitalizations for patients with heart failure and left ventricular systolic dysfunction. The
fficacy of ARB therapy has been strengthened by several large-scale prospective randomized clinical trials demonstrating reduction in mortality and hospitalization
or heart failure among patients with heart failure and LVSD. ACE inhibitors should be prescribed to all patients with HF due to LV systolic dysfunction unless
hey have a contraindication to their use or have been shown to be unable to tolerate treatment with these drugs. ACE inhibitors remain the first choice for
nhibition of the renin-angiotensin system in chronic HF, but ARBs can now be considered a reasonable alternative (13,16,17). Even if the patient has responded
avorably to the diuretic, treatment with ACE inhibitor or ARBs should be initiated and maintained in patients who can tolerate them, because they have been
hown to favorably influence the long-term prognosis of HF.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
ngiotensin converting enzyme inhibitors are recommended for all patients with current or prior symptoms of HF and reduced LVEF, unless
ontraindicated (Level of Evidence: A).
lass IIa
n ARB should be administered to post-MI patients without HF who are intolerant of ACEIs and have a low LVEF (Level of Evidence: B).
Referenced Recommendation(s)
MS/JCAHO Core Measure: Heart Failure, HF-3: ACEI or ARB for LVSD (9).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
Challenges to Implementation
Determination of who has LVEF 0.40 is a potential challenge to implementation, as well as how this can be reasonably, consistently, reliably located
in the patient record. Also, future updates may consider whether the determination of ACEI or ARB use is made only at discharge (discharge medication
list) or whether additional credit should be provided for in-hospital initiation and titration.
Ambiguity regarding what constitutes contraindication and difficulty identifying the contraindications in the medical record.
Quality improvement efforts also should consider whether prescription of only specific agent or specific dose-ranges (based on clinical trial evidence) should be
encouraged.
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Heart failure patients with chronic/recurrent AF and without warfarin contraindications who are prescribed warfarin at discharge
umerator Heart failure patients in the denominator for whom warfarin is prescribed at discharge
enominator Heart failure patients discharged with chronic or recurrent atrial fibrillation.
Included populations:
● Discharges with an ICD-9-CM Principal Diagnosis Code for heart failure as defined in Table 3, AND
● Chart documentation of chronic or recurrent atrial fibrillation.
Excluded populations:
● Patients less than 18 years of age;
● Patients transferred to another acute care hospital or federal hospital;
● Patients who expired;
● Patients who left against medical advice;
● Patients discharged to hospice;
● Contraindication to warfarin which include:
– Allergy,
– Pregnancy,
– Risk of bleeding (such as active peptic ulcer disease); hemorrhagic stroke; other hemorrhage; hepatic failure; bleeding
disorder; metastatic cancer; recent or planned surgery or biopsy procedure; other physician-documented bleeding risk,
– Risk of fall documented by physician,
– Psychosocial concerns (such as active psychosis; terminal illness/comfort care only; alcoholism or drug abuse), or
– Other potential contraindication (seizure disorder; malignant hypertension; intracranial aneurysm, repaired or
unrepaired, and others); or
● Documentation of reason(s) by a physician, nurse practitioner, or physician assistant for not prescribing warfarin.
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
n patients with symptomatic HF, the prevalence of AF ranges from 10 to 30 percent, with the highest incidence among those with the most severe HF.
hese patients are at risk of systematic embolization and stroke. Anticoagulation with warfarin is most justified in patients with HF who have experienced
previous embolic event or who have paroxysmal or chronic atrial fibrillation.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
hysicians should prescribe anticoagulants in patients with HF who have paroxysmal or persistent atrial fibrillation or a previous thromboembolic event
Level of Evidence: A).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
This is a test measure.
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Heart failure patients discharged home with written instructions or educational material given to the patient or care giver at discharge or
during the hospital stay addressing all of the following: activity level, diet, discharge medications, follow-up appointment,
weight monitoring, and what to do if symptoms worsen
umerator Heart failure patients with documentation that they or their caregivers were given written discharge instructions or other
educational material addressing all of the following:
1. Activity level
2. Diet
3. Discharge medications
4. Follow-up appointment
5. Weight monitoring
6. What to do if symptoms worsen
enominator Heart failure patients discharged home.
Included populations:
● Discharges with an ICD-9-CM Principal Diagnosis Code for heart failure as defined in Table 3.
● A discharge to home or home care.
Excluded populations:
● Patients less than 18 years of age
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
ducation of heart failure patients and their families is critical. Failure of these patients to comply with physician’s and other healthcare providers’
nstructions is sometimes a cause of HF exacerbation. A significant cause of patient’s failure to comply is lack of understanding. It is, therefore, incumbent
n health care professionals to be certain that patients and their families have an understanding of the causes of heart failure, prognosis, therapy, dietary
estrictions, activity, importance of compliance, and the signs and symptoms of recurrent heart failure. Thorough discharge planning is associated with
mproved patient outcomes (11).
Reference Recommendation(s)
MS/JCAHO Core Measure: Heart Failure, HF-1: Discharge Instructions (9).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
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Heart failure patients with a history of smoking cigarettes, who are given smoking cessation advice or counseling during hospital stay
[For purposes of this measure, a smoker is defined as someone who has smoked cigarettes anytime during the year prior to hospital arrival.]*
umerator Heart failure patients (cigarette smokers) who receive smoking cessation advice or counseling during the hospital stay.
enominator Heart failure patients with a history of smoking cigarettes anytime during the year prior to hospital arrival.
Included populations:
● Discharges with an ICD-9-CM Principal Diagnosis Code for heart failure as defined in Table 3, AND
● A history of smoking cigarettes anytime during the year prior to hospital arrival.
Excluded populations:
● Patients less than 18 years of age;
● Patients transferred to another acute care hospital or federal hospital;
● Patients who expired;
● Patients who left against medical advice;
● Patients discharged to hospice.
eriod of assessment Hospital discharge.
ources of data Administrative data and medical records.
Rationale
moking is correlated with increased risk of coronary artery disease and heart failure. Heart failure patients who are smokers should be given smoking
essation advice or counseling during the hospital stay. In addition, resources to assist in quitting smoking should be supplied, such as nicotine replacement
herapy, referral to a smoking cessation counselor or support group, and smoking cessation pharmacotherapy.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
atients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol
onsumption, and illicit drug use) (Level of Evidence: C).
Reference Recommendation(s)
MS/JCAHO Core Measure: Heart Failure, HF-4: Adult Smoking Cessation Advice/Counseling (9).
Method of Reporting
ggregate rate (standard error) generated from count data reported as a proportion.
There is interest in expanding this definition beyond cigarette smoking that would include cigars and pipes. At this time, efforts are being made to keep the measures aligned
ith the referenced recommendations.
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1. Initial Laboratory Tests*
Initial laboratory evaluation of patients with newly diagnosed HF
umerator Patients for whom initial laboratory testing was performed. Laboratory testing should include the following:
● Complete blood count,
● Urinalysis,
● Serum electrolytes (including calcium and magnesium),
● Blood urea nitrogen,
● Serum creatinine,
● Blood glucose,
● Liver function test, and
● Thyroid-stimulating hormone.
enominator All patients, 18 years of age and older, with newly diagnosed HF during the reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet
Rationale
aboratory testing may reveal important heart failure etiologies, the presence of disorders or conditions that can lead to or exacerbate HF. Laboratory testing
ould also reveal important modulators of therapy. The initial evaluation of patients with heart failure should include all of the testing indicated in the
uideline recommendation.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
nitial laboratory evaluation of patients presenting with HF should include complete blood count, urinalysis, serum electrolytes (including calcium and
agnesium), blood urea nitrogen, serum creatinine, fasting blood glucose (glycohemoglobin), lipid profile, liver function tests, and thyroid-stimulating
ormone (Level of Evidence: C).
Method of Reporting
er patient
Whether or not initial laboratory testing was performed.
er patient population
Percentage of all patients for whom initial laboratory testing was performed.
This measure has been designated strictly as a quality improvement measure and requires prospective data collection.
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Chronic Heart Failure in the Adult: ACC/AHA Performance Measures September 20, 2005:1144–782. Left Ventricular Systolic (LVS) Function Assessment
Heart failure patients with documentation that LVS function has been assessed
umerator Patients in whom quantitative or qualitative results of a recent or prior (any time in the past) assessment of LVS
function is documented.
enominator All patients, 18 years of age and older, with HF.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
easurement of left ventricular function is a crucial step in the evaluation and management of heart failure patients. Evaluation of patients with heart failure
hould include a measurement of left ventricular systolic function. Patients with a left ventricular ejection fraction less than 40% or with moderately or
everely depressed left ventricular systolic function are generally considered to have depressed systolic function warranting consideration of specific therapy.
The single most useful diagnostic test in the evaluation of patients with HF and left ventricular systolic function is the comprehensive two-dimensional
chocardiogram coupled with Doppler flow studies to determine whether the primary abnormality is pericardial, myocardial or valvular. A comprehensive
chocardiographic evaluation is important, since it is common for patient to have more than one cardiac abnormality that contributes to the development
f HF. Furthermore, the study serves as a baseline for comparison to assess long-term effects of therapeutic interventions or changes associated with
ignificant clinical events.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
wo-dimensional echocardiography with Doppler should be performed during initial evaluation of patients presenting with HF to assess LVEF, LV size,
all thickness, and valve function. Radionuclide ventriculography can be performed to assess LVEF and volumes (Level of Evidence: C).
Method of Reporting
er patient:
Quantitative or qualitative results of LVS function assessment.
er patient population:
Percentage of patients with quantitative or qualitative results of LVS function assessment recorded.
Challenges to Implementation
n the stable heart failure patient, the LVS function assessment carries over from year to year. Since older measurements are still valid if the patient has
ot experienced a change in clinical status, the use of a patient flow sheet or data collection tool that includes notation of most recent LVS function
ssessment results is suggested.
ND
P
S
W
A
o
e
b
s
A
C
I
m
A
P
●
P
●
1163JACC Vol. 46, No. 6, 2005 Bonow et al.
September 20, 2005:1144–78 Chronic Heart Failure in the Adult: ACC/AHA Performance Measures3. Weight Measurement
Measurement of patient’s weight at each outpatient visit to assess change in volume status
umerator Patient visits with weight measurement recorded.
enominator All patient visit for patients 18 years of age and older with HF.
Excluded Populations:
● Patient visits in which physician was unable to weight patient.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
eight and fluid monitoring is essential for heart failure patients. Significant changes in weight are often indications that the patient is in fluid overload.
thorough physical examination is recommended to identify cardiac and non-cardiac disorders that may accelerate the progression of HF. A careful history
f heart failure patients focused on volume status plays a pivotal role in determining the need for or adjustment of diuretic therapy and in detecting sodium
xcesses or deficiencies that may limit efficacy and decrease the tolerability of drugs used to treat HF. Short-term changes in fluid status are best assessed
y measuring changes in body weight. However, changes in body weight may be less reliable during long periods of follow-up, because many patients lose
keletal muscle mass and body fat as the disease progresses due to the development of cardiac cachexia.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
nitial examination of patients presenting with HF should include assessment of the patient’s volume status, orthostatic blood pressure changes,
easurement of weight and height, and calculation of body mass index (Level of Evidence: C).
ssessment should be made at each visit of the volume status and weight of a patient with HF. (Level of Evidence: C).
Method of Reporting
er patient:
Number of visits with weight measurement recorded/number of visits.
er patient population:
Percentage of patient visits with weight measurement recorded.
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Chronic Heart Failure in the Adult: ACC/AHA Performance Measures September 20, 2005:1144–784. Blood Pressure Measurement
Measurement of patient’s blood pressure at each outpatient visit
umerator Patient visits with blood pressure measurement recorded.
enominator All patient visits for patients 18 years of age and older with HF.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
ystematic hypertension is a major risk factor for heart failure increasing its development by two- to four-fold. A complete history and physical examination
re the first steps in evaluating the structural abnormality or cause responsible for the development of HF. Direct inquiry may reveal prior or current evidence
f MI, valvular disease, or congenital heart disease, whereas examination of the heart may suggest the presence of cardiac enlargement, murmurs, or a third
eart sound.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
thorough history and physical examination should be obtained/performed in patients presenting with HF to identify cardiac and noncardiac disorders
r habits that might cause or accelerate the development of HF or accelerate the progression of HF (Level of Evidence: C).
Method of Reporting
er patient:
Number of visits with blood pressure measurement recorded/number of visits.
Most recent systolic and diastolic blood pressure values.
er patient population:
Percentage of patient visits with a blood pressure measurement recorded.
Distribution of systolic and diastolic blood pressure values.
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September 20, 2005:1144–78 Chronic Heart Failure in the Adult: ACC/AHA Performance Measures5. Assessment of Clinical Symptoms of Volume Overload (Excess)
Assessment of patient’s clinical symptoms of volume overload at each outpatient visit
(standardized scale or assessment tool may be used)
umerator Patient visits with assessment of clinical symptoms of volume overload (excess). Assessment for presence or absence of
symptoms of volume overload must include:
● Dyspnea, or
● Orthopnea, or
● Documentation of standardized scale or completion of assessment tool.
enominator All patients visits for patients, 18 years of age and older, with HF.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
careful history of heart failure patients focused on volume status plays a pivotal role in determining the need for or adjustment of diuretic therapy and
n detecting sodium excesses or deficiencies that may limit efficacy and decrease the tolerability of drugs used to treat HF. Volume overload is a common
eason for repeat hospitalization for patients with heart failure. The finding of clear lung fields on physical examination of a patient with chronic heart failure
hould not suggest that fluid retention has been adequately treated.
Once the nature and cause of the structural abnormalities leading to the development of HF have been defined, physicians should focus on the clinical
ssessment of patients, both during the initial presentation and during subsequent visits. This ongoing review of the patient’s clinical status is critical to the
ppropriate selection and monitoring of treatments.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
thorough history and physical examination should be obtained/performed in patients presenting with HF to identify cardiac and noncardiac disorders
r behaviors that might cause or accelerate the development or progression of HF (Level of Evidence: C).
nitial examination of patients presenting with HF should include assessment of the patient’s volume status, orthostatic blood pressure changes,
easurement of weight and height, and calculation of body mass index (Level of Evidence: C).
ssessment should be made at each visit of the volume status and weight of a patient with HF (Level of Evidence: C).
Method of Reporting
er patient:
Number of visits with assessment of clinical symptoms of volume overload (excess)/number of visits.
er patient population:
Percentage of patient visits with assessment of clinical symptoms of volume overload (excess).
Challenges to Implementation
ompletion of history focused on volume status.
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Chronic Heart Failure in the Adult: ACC/AHA Performance Measures September 20, 2005:1144–786. Assessment of Clinical Signs of Volume Overload (Excess)
Completion of a physical examination pertaining to volume status assessment in patients diagnosed with HF at each outpatient visit
(standardized scale or assessment tool may be used)
umerator Patient visits with assessment of clinical signs of volume overload (excess).
Assessment for presence or absence of signs of volume overload must include:
● Peripheral edema, or
● Rales, or
● Hepatomegaly, or
● Ascites, or
● Assessment of jugular venous pressure, or
● S3 gallop, or
● S4 gallop.
enominator All patient visits for patients, 18 years of age and older, with HF.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
careful history of heart failure patients focused on volume status plays a pivotal role in determining the need for or adjustment of diuretic therapy and
n detecting sodium excesses or deficiencies that may limit efficacy and decrease the tolerability of drugs used to treat HF. Volume overload is a common
eason for repeat hospitalization for patients with heart failure. The finding of clear lung fields on physical examination of a patient with chronic heart failure
hould not suggest that fluid retention has been adequately treated.
Once the nature and cause of the structural abnormalities leading to the development of HF have been defined, physicians should focus on the clinical
ssessment of patients, both during the initial presentation and during subsequent visits. This ongoing review of the patient’s clinical status is critical to the
ppropriate selection and monitoring of treatments.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
thorough history and physical examination should be obtained/performed in patients presenting with HF to identify cardiac and noncardiac disorders
r behaviors that might cause or accelerate the development or progression of HF (Level of Evidence: C).
nitial examination of patients presenting with HF should include assessment of the patient’s volume status, orthostatic blood pressure changes,
easurement of weight and height, and calculation of body mass index (Level of Evidence: C).
ssessment should be made at each visit of the volume status and weight of a patient with HF (Level of Evidence: C).
Method of Reporting
er patient:
Number of visits with assessment of clinical signs of volume overload (excess)/number of visits.
er patient population:
Percentage of patient visits with assessment of clinical signs of volume overload (excess).
Challenges to Implementation
ompletion of physical examination focused on volume status.
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September 20, 2005:1144–78 Chronic Heart Failure in the Adult: ACC/AHA Performance Measures7. Assessment of Activity Level
Evaluation of the impact of HF on activity level at each outpatient visit
(standardized scale or assessment tool may be used)
umerator Patient visits with assessment of current level of activity OR documentation of standardized scale or completion
of assessment tool.*
enominator All patient visits for patients aged 18 years with HF.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
valuation of function longitudinally is necessary to track improvement or worsening as a basis for treatment decisions. A thorough history is recommended
o identify cardiac and non-cardiac disorders that may accelerate the progression of HF. Inquiry about the patient’s activity level is important in the
ssessment of the patient’s functional capacity and plays a role in the general management of patients with HF.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
n patients presenting with HF, initial assessment should be made of a patient’s ability to perform routine and desired activities of daily living (Level of
vidence: C).
Method of Reporting
er patient:
Number of visits with assessment of activity level/number of visits.
er patient population:
Percentage of patient visits with assessment of activity level.
Standardized scale or assessment tools may include the New York Heart Association functional classification of congestive heart failure (level of activity only); Kansas City
ardiomyopathy Questionnaire; Minnesota Living with Heart Failure Questionnaire; or Chronic Heart Failure Questionnaire (Guyatt).
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Chronic Heart Failure in the Adult: ACC/AHA Performance Measures September 20, 2005:1144–788. Patient Education
Percentage of patients who were provided with patient education on disease management and health behavior changes
during one or more visits within the period of assessment
umerator Patients who were provided with written and/or verbal education at one or more visit(s). Patient education
should include one or more of the following:
● Weight monitoring;
● Diet (sodium restriction);
● Symptom management;
● Physical activity;
● Smoking cessation;
● Medication instruction;
● Minimizing or avoiding use of NSAIDs;
● Referral for visiting nurse or specific educational or management programs; or
● Prognosis/end-of-life issues.
enominator All patients 18 years of age and older, with HF and with one or more visit(s).
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
atient education and close supervision is recommended for patients with HF to reduce the likelihood of noncompliance and lead to the detection of
hanges in body weight or clinical status early enough for effective treatment to be instituted.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
atients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol
onsumption, and illicit drug use) (Level of Evidence: C).
Method of Reporting
er patient:
Whether or not patient education was provided.
er patient population:
Percentage of patients who were provided with patient education on disease management and health behavior changes during one or more visits.
Challenges to Implementation
Lack of chart documentation of education activities and patient counseling.
Use of patient’s education measure for accountability purposes.
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September 20, 2005:1144–78 Chronic Heart Failure in the Adult: ACC/AHA Performance Measures9. Beta-Blocker Therapy
Prescription of beta-blockers in patients with HF and left ventricular systolic dysfunction (LVSD)
umerator Patients who were prescribed beta-blocker therapy.
enominator All HF patients, 18 years of age and older, with LVSD, defined as LVEF 40% or with moderately or severely
depressed left ventricular systolic function.
Included populations:
● Patients with HF and LVSD, defined as LVEF 40% or with moderately or severely depressed left
ventricular systolic function.
Excluded populations:
● Documentation of medical reason(s) by a physician, nurse practitioner, or physician assistant for not
prescribing beta-blocker; or
● Documentation of patient reason(s) (e.g., economic, social, and/or religious) for not prescribing beta-blocker
therapy.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
eta-blockers should be prescribed to all patients with stable HF due to LVSD unless they have a contraindication to their use or have been shown to be
nable to tolerate treatment with these drugs. Treatment should be initiated in the outpatient setting as soon as the LV dysfunction is diagnosed, even when
ymptoms are mild. Long-term treatment with beta-blockers can lessen the symptoms of HF, improve the clinical status of patients, reduce the risk of death,
nd reduce the combined risk of death or hospitalization. These benefits of beta-blockers were seen in patients with or without coronary artery disease and
n patients with or without diabetes.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
eta-blockers (using 1 of the 3 proven to reduce mortality, i.e., bisoprolol, carvedilol, and sustained release metoprolol succinate) are recommended for all
table patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated (Level of Evidence: A).
Method of Reporting
er patient:
Whether or not patient with LVSD was prescribed beta-blocker therapy.
er patient population:
Percentage of all HF patients with LVSD who were prescribed beta-blocker therapy.
Percentage of patients with LVSD who were prescribed beta-blocker therapy, with all denominator exclusions applied.
Challenges to Implementation
dentification of contraindications in medical records.
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Chronic Heart Failure in the Adult: ACC/AHA Performance Measures September 20, 2005:1144–7810. ACE Inhibitor or Angiotensin Receptor Blocker (ARB) for Patients with Heart Failure Who Have
Left Ventricular Systolic Dysfunction (LVSD)
Prescription of ACE inhibitor or ARB for management of outpatient HF patients with LVSD
umerator Patients who were prescribed ACE inhibitor or ARB therapy.
enominator All HF patients, 18 years of age and older, with LVSD, defined as LVEF 40% or with moderately or severely
depressed left ventricular systolic function.
Included populations:
● Patients with HF and LVSD, defined as LVEF 40% or with moderately or severely depressed left
ventricular systolic function.
Excluded populations:
● Documentation of medical reason(s) by a physician, nurse practitioner, or physician assistant for not
prescribing ACE inhibitor and for not prescribing ARB therapy.
● Documentation of patient reason(s) (e.g. economic, social, and/or religious) for not prescribing ACE inhibitor
and for not prescribing ARB therapy.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
CE inhibitors have been shown to decrease morbidity, mortality, and hospitalizations for patients with heart failure and left ventricular systolic
ysfunction. The efficacy of ARB therapy has been strengthened by several large-scale prospective randomized clinical trials demonstrating reduction in
ortality and hospitalization for heart failure among patients with heart failure and LVSD. ACEIs should be prescribed to all patients with HF due to
V systolic dysfunction unless they have a contraindication to their use or have been shown to be unable to tolerate treatment with these drugs. ACEIs
emain the first choice for inhibition of the renin-angiotensin system in chronic HF, but ARBs can now be considered a reasonable alternative (13). Even
f the patient has responded favorably to the diuretic, treatment with ACEI should be initiated and maintained in patients who can tolerate them, because
hey have been shown to favorably influence the long-term prognosis of HF.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
ngiotensin converting enzyme inhibitors are recommended for all patients with current or prior symptoms of HF and reduced LVEF, unless
ontraindicated (Level of Evidence: A).
n ARB should be administered to post-MI patients without HF who are intolerant of ACEIs and have a low LVEF (Level of Evidence: B).
lass IIa
ngiotensin II receptor blockers are reasonable to use as alternatives to ACEIs as first-line therapy for patients with mild to moderate HF and reduced
VEF, especially for patients already taking ARBs for other indications (Level of Evidence: A).
Method of Reporting
er patient:
Whether or not patient with LVSD was prescribed ACE inhibitor or ARB therapy.
er patient population:
Percentage of all patients with LVSD who were prescribed ACE inhibitor or ARB therapy.
Percentage of patients with LVSD who were prescribed ACE inhibitor or ARB therapy, with all denominator exclusions applied.
Challenges to Implementation
Difficulty locating information regarding LVSD.
Ambiguity regarding what constitutes contraindication.
Difficulty sorting through the chart to find the contraindications.
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September 20, 2005:1144–78 Chronic Heart Failure in the Adult: ACC/AHA Performance Measures11. Warfarin Therapy for Patients with Atrial Fibrillation (AF)
Use of warfarin in patients with both HF and AF
umerator Patients who were prescribed warfarin therapy within the specified period of assessment.
enominator All HF patients, 18 years of age and older, with paroxysmal or chronic atrial fibrillation
Included populations:
● Patients with HF and paroxysmal or chronic atrial fibrillation
Excluded populations:
● Documentation of medical reason(s) by a physician, nurse practitioner, or physician assistant for not prescribing warfarin,
or
● Documentation of patient reason(s) for not prescribing warfarin.
eriod of assessment Per reporting year.
ource of data EHRS, retrospective paper medical records, prospective flowsheet.
Rationale
n patients with symptomatic HF, the prevalence of AF ranges from 10 to 30 percent, with the highest incidence among those with the most severe HF.
hese patients are at risk of systematic embolization and stroke. Anticoagulation with warfarin is most justified in patients with HF who have experiences
previous embolic event or who have paroxysmal or chronic atrial fibrillation.
Clinical Recommendation(s)
CC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult (8).
lass I
hysicians should prescribe anticoagulants in patients with HF who have paroxysmal or persistent atrial fibrillation or a previous thromboembolic event
Level of Evidence: A).
Method of Reporting
er patient:
Whether or not patient with paroxysmal or chronic atrial fibrillation was prescribed warfarin therapy.
er patient population:
Percentage of all patients with paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.
Percentage of patients with paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy, with all denominator exclusions applied.
Challenges to Implementation
Tracking medical record for the relevant data.
Interfacing with laboratory information systems.
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Chronic Heart Failure in the Adult: ACC/AHA Performance Measures September 20, 2005:1144–78PPENDIX C. Sample Rating Form and Rating Form Guide
ame of Measure:
linical Rationale:
umerator:
enominator:
easure:
ate this measure on the following criteria.
Disagree
Moderate
Agreement Agree
1 2 3 4 5
seful in Improving Patient Outcomes
. Evidence-based: The scientific basis of the measure is well established. 1 2 3 4 5
. Interpretable: The results of the measure are interpretable by practitioners. 1 2 3 4 5
. Actionable: The measure addresses an area that is under the practitioner’s
control.
1 2 3 4 5
easure Design
. Denominator: The patient group to whom this measure applies
(denominator) is clinically meaningful.
1 2 3 4 5
. Numerator: The definition of conformance for this measure is clinically
meaningful.
1 2 3 4 5
. Validity:
a. The measure appears to measure what it is intended to (face validity). 1 2 3 4 5
b. The measure captures most meaningful aspects of care (content validity). 1 2 3 4 5
c. The measure correlates well with other measures of the same aspect of
care (construct validity).
1 2 3 4 5
. Reliability: The measure is likely to be reproducible across organizations
and delivery settings.
1 2 3 4 5
easure Implementation
. Feasibility:
a. The data required for the measure is likely to be obtained with
reasonable effort.
1 2 3 4 5
b. The data required for the measure is likely to be obtained at reasonable
cost.
1 2 3 4 5
c. The data required for the measure is likely to be obtained within the
period allowed for data collection.
1 2 3 4 5
verall Assessment Do Not Include Could Include Must Include
onsidering your assessment of this measure on all dimensions above, rate
his measure overall for inclusion into the ACC/AHA Heart Failure
erformance Measurement Set.
1 2 3 4 5
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Attribute of Performance Considerations
seful in Improving Patient Outcomes
. Evidence-based: The scientific basis of the
measure is well established.
This can be confirmed by explicit reference to a published clinical practice guideline.
. Interpretable: The results of the measure are
interpretable by practitioners.
This is your assessment of the degree with which a provider can clearly understand
what the results mean and can take action if necessary.
. Actionable: The measure addresses an area that is
under the practitioner’s control.
This is your assessment of the degree with which a provider is empowered and can
influence the activities of the health care system toward improvement.
easure Design
. Denominator: The patient group to whom this
measure applies (denominator) is clinically
meaningful.
Depending upon intended use of the measure, the data source, any inclusion or
exclusion criteria, and sampling frames are explicit. These criteria used must be
clinically meaningful. An algorithm for determining the denominator may be
present.
. Numerator: The definition of conformance for this
measure is clinically meaningful.
The numerator may be specified using either explicit or implicit criteria. These
criteria used must be clinically meaningful. An algorithm for determining the
numerator may be present.
. Validity:
This can be confirmed by your judgment of the clarity and comprehensiveness of
the measure. For those measures that have been actually tested for validity, you may
see indications of specific testing such as comparisons with the results of other
methods, criterion or gold standard validity testing, and criterion validity testing.
There may also be documentation that the health care construct underlying the
measure is associated with important health care processes/outcomes.
a. The measure appears to measure what it is
intended to (face validity).
b. The measure captures most meaningful aspects
of care (content validity).
c. The measure correlates well with other measures
of the same aspect of care (construct validity).
. Reliability: The measure is likely to be
reproducible across organizations and delivery
settings.
This can be confirmed by specific tests undertaken by the measure developers. For
those measures that have been actually tested for reliability, you may see indications
of types of reliability testing such as test-retest reliability, inter-rater reliability, data
accuracy checks, and internal consistency analyses. If the measure has not been used
in practice, indicate the degree of likelihood that it is reproducible.
easure Implementation
. Feasibility: From your perspective, the required data can be typically abstracted from patient
charts or there are national registries, databases readily available. For those measures
actually being used, there is information on the data collection approach and the
system required to support the measure.
a. The data required for the measure is likely to be
obtained with reasonable effort.
b. The data required for the measure is likely to be
obtained at reasonable cost.
c. The data required for the measure is likely to be
obtained within the period allowed for data
collection.
verall Assessment
onsidering your assessment of this measure on all
imensions above, rate this measure inclusion in the
CC/AHA Heart Failure Performance Measurement
et.
Consider a balance in the continuum of care. Consider overall purpose of the
measurement set and the intended user.
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ndustry
Committee Member Research Grant
Speakers Bureau/
Honoraria/
Expert Witness
Stock
Ownership Board of Directors
Consultant/
Advisory
Member
r. Susan J. Bennett None None None None None
r. Robert O. Bonow None None None None None
r. Donald E. Casey, Jr. ● Agency for Healthcare
Research and Quality
(focused on improving
heart failure care in a
large medical system)
None ● Bristol-Myers
Squibb
● Merck (Keogh)
● Health Foundation,
Greater Cincinnati
Amercian College of
Medical Quality
● 3M Corporation
r. Mark A. Hlatky None None None None None
r. Theodore G.
Ganiats
None None None None None
r. Marvin A.
Konstam
● Glaxo Smith Kline ● Astra Zeneca
● Glaxo Smith
Kline
● Merck
● Novartis
None None ● Astra Zeneca
● Glaxo Smith
Kline
● Merck
● Novartis
r. Costas T. Lambrew None None None None None
r. Sharon-Lise T.
Normand
None None None None None
r. Ileana L. Piña None None None None None
r. Martha J. Radford None None None None None
r. Andrew L. Smith ● Medtronic ● Medtronic
● Guidant
None None ● Medtronic
r. Lynne Warner
Stevenson
● Medtronic None None None ● Medtronic
● Novacardia
● Scios
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Outpatient Measures Only)
Committee Member Research Grant
Speakers Bureau/
Honoraria/
Expert Witness
Stock
Ownership Board of Directors
Consultant/
Advisory Member
r. H. Christopher
Alexander III
None ● Office of Hearings
& Appeals, Social
Security
Administration
None None None
r. Henry R. Black None None None None None
r. Robert O. Bonow None None None None None
r. Joel V. Brill None None None None ● Value Options
● CORF Services
● Kimberly-Clark
r. Charles Cefalu None ● Novartis
● Pfizer
● Proctor and Gamble
● Wyeth-Ayerst
None None ● Novartis
● Proctor and Gamble
● Wyeth-Ayerst
r. Stephen Daniels None None None None ● Abbott Laboratories
● Able Laboratories
r. A. Todd Davis None None None None None
r. Joseph P. Drozda None None ● Centene
Corp.
None None
r. Ray E. Gifford None None None None None
r. William E. Golden None None None ● American College
of Physicians
National Quality
Forum
None
r. William E. Haley None None None ● Renal Physicians’
Association
None
r. Richard Hellman None None None None None
r. William J Hueston None None None None None
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